194
Participants
Start Date
December 31, 2012
Primary Completion Date
November 22, 2019
Study Completion Date
March 6, 2020
Gantenerumab
Subcutaneously every 4 weeks at escalating doses
Solanezumab
Intravenous infusion every 4 weeks at escalating doses
Matching Placebo (Gantenerumab)
Subcutaneous injection of placebo every 4 weeks
Matching Placebo (Solanezumab)
Intravenous infusion of placebo every 4 weeks
Neuroscience Research Australia, Randwick
Mental Health Research Institute, Melbourne
The McCuster Foundation of Alzheimer's Disease Research, Nedlands
Hospital Clínic I Provincial de Barcelona, Barcelona
Columbia University, New York
University of Pittsburgh, Pittsburgh
Emory University, Atlanta
CHU de Toulouse - Hôpital Purpan, Toulouse
University of Alabama in Birmingham, Birmingham
Indiana University School of Medicine, Indianapolis
Hopital Roger Salengro - CHU Lille, Lille
Washington University in St. Louis, St Louis
Groupe Hospitalier Pitie-Salpetriere, Paris
Hopital Neurologique Pierre Wertheimer, Bron
CHU de Rouen - Hôpital Charles Nicolle, Rouen
University of California San Diego Medical Center, La Jolla
University of Washington, Seattle
Yale University School of Medicine, New Haven
Butler Hospital, Providence
UBC Hospital, Vancouver
Sunnybrook Health Sciences Centre, Toronto
McGill Center for Studies in Aging, Verdun
St Vincent's University Hospital, Dublin
University of Puerto Rico, School of Medicine, San Juan
The National Hospital for Neurology and Neurosurgery, London
Collaborators (1)
Eli Lilly and Company
INDUSTRY
Hoffmann-La Roche
INDUSTRY
Alzheimer's Association
OTHER
National Institute on Aging (NIA)
NIH
Avid Radiopharmaceuticals
INDUSTRY
Accelerating Medicines Partnership (AMP)
OTHER
Washington University School of Medicine
OTHER